Loading organizations...
Key people at POC.
POC engineers premium protective gear, including helmets, apparel, and accessories, primarily for skiing and cycling. The company operates as a safety and sports performance pioneer, utilizing extensive research and rigorous testing to develop innovative products. Their technical approach focuses on reducing the consequences of accidents through advanced material science and design.
Stefan Ytterborn founded POC in Stockholm, Sweden, in 2005. His insight identified a critical need for superior protection in action sports, compelling the company to minimize accident impacts for athletes. Ytterborn’s vision integrated cutting-edge science and design, creating products that safeguard individuals and empower their athletic pursuits.
POC's portfolio serves a wide range of users, from elite professional athletes to recreational enthusiasts globally. The company's long-term vision involves continually advancing safety standards within the sports industry, ensuring innovative solutions contribute to a safer, more confident experience for active lifestyles.
Key people at POC.
PoC Capital, LLC is a single-family office based in Woodside, California, founded in 2015 by biotech executive Daron Evans.[1] It manages family capital from Evans' roles in public and private life-science enterprises, focusing exclusively on micro- and small-cap public life science companies by providing proof-of-concept (PoC) funding for clinical trials in exchange for equity and warrants.[1][2] The firm's mission centers on investing in product candidates that improve patient well-being, prioritizing strong management, clear mechanisms of action, and validated development plans to unlock asset value through safety and efficacy data.[2] In the startup ecosystem, PoC Capital bridges critical funding gaps for emerging therapeutics developers, enabling pivotal clinical validation that often attracts larger follow-on investments.[1]
PoC Capital traces its roots to 2015, when Daron Evans, a seasoned biotech executive, established it as the Evans Family Office in Woodside, CA.[1] Evans built his expertise through leadership, investment, and advisory positions across life-science firms, generating the family capital that fuels the office's direct investments.[1] The firm's focus evolved to target proof-of-concept clinical trials for small public companies, a niche honed from Evans' deep industry experience in therapeutics development.[1][2] This hands-on approach reflects a pivot from broader biotech involvement to specialized, high-impact PoC funding that de-risks early-stage assets.[2]
PoC Capital rides the wave of precision medicine and biotech derisking, where proof-of-concept trials are essential to validate novel therapeutics amid rising R&D costs and investor scrutiny.[2] Timing is ideal in a market favoring public micro-caps, as smaller firms struggle with trial funding post-seed but pre-Series A, amplified by post-pandemic biotech funding droughts.[1] Favorable forces include regulatory pushes for faster approvals (e.g., FDA breakthroughs) and demand for patient-centric innovations, positioning PoC Capital to catalyze ecosystem growth by enabling trial data that draws institutional capital.[2] It influences the landscape by sustaining small innovators, fostering a pipeline of viable assets that larger pharma can acquire or partner with.
PoC Capital is primed to expand its niche as biotech rebounds, with AI-driven trial design and personalized therapies amplifying PoC's value in accelerating validation.[2] Upcoming trends like modular trials and real-world evidence will shape its portfolio, potentially evolving toward hybrid public-private deals amid volatile markets. Its influence may grow by mentoring more first-time biotech leaders, solidifying Evans' model as a blueprint for family-office impact—ultimately fueling patient breakthroughs from overlooked small-caps.[1][2]
